Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer

Squamous Cell Carcinoma of the Head and Neck Clinical Trial

— GuidedbyLight  

Official title:

Guided by Light: Optimizing Surgical Excision of Oral Cancer Using Real-time Fluorescence Imaging

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04191460
• Other study ID #: 12175
• Secondary ID: 2019-003416-30
• Status: Recruiting
• Phase: Phase 2
• Start date: July 12, 2022
• Est. completion date: March 1, 2025

Study information

• Verified date: February 2024
• Source: Erasmus Medical Center
• Contact: Stijn Keereweer, MD PhD
• Phone: 010 704 13 57
• Email: s.keereweer[@]erasmusmc.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a two-staged clinical trial to investigate the feasibility of intraoperative Fluorescence Imaging (FLI) to adequately assess tumor margins in patients with oral cancer using cRGD-ZW800-1.

Description:

Work package I:

In WP-I, the preferred dose of the agent for imaging of margins in oral cancer will be determined. The signal-to-noise ratio will be determined in dose group A (n=7), which will receive 0.05 mg/kg of the tracer, 16-20 hours before surgery. After an interim evaluation of this ratio, the second dose group B (n=7) will receive either a higher or a lower dosage (to be determined) of the tracer. After inclusion of all patients (n=14), the dose with the highest intraoperative signal-to-noise ratio will be selected.

Work package II:

In WP-II, an expansion cohort (n=14) will be added to the group of patients that had received the selected dose in WP-I. In this group of 21 patients, it will be determined if FLI can improve the rate of adequate surgical resection margins. As secondary research questions, the following aspects will be assessed:

• sensitivity, specificity, positive and negative predictive values of FLI;

• colocalization with immunohistochemistry;

• change in surgical management; incremental operation time;

• FLI of excised cervical lymph nodes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 28
• Est. completion date: March 1, 2025
• Est. primary completion date: September 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with biopsy-proven squamous cell carcinoma of the oral cavity, eligible for surgical resection of the primary tumor;

2. = 18 years of age;

3. Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations;

4. Screening ECG and clinical laboratory test results are within normal limits, or if any are outside of normal limits they are considered to be clinically insignificant.

Exclusion Criteria:

1. Previous surgery, chemotherapy or radiotherapy to the oral cavity;

2. History of a clinically significant allergy or anaphylactic reactions to any of the components of the agent.

3. Patients pregnant or breastfeeding, lack of effective contraception in male or female patients with reproductive potential;

4. Patients with renal insufficiency (eGFR<60);

5. Patients with a previous kidney transplantation in the medical history;

6. Immuno-compromised patients who do not have the ability to respond normally to an infection due to an impaired on weakened immune system, caused by either a pre-existing disease or concomitant medications;

7. Any condition that the investigator considers to be potentially jeopardizing the patient's well-being or the study objectives.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Lip Neoplasms
• Mouth Neoplasms
• Oral Cancer
• Squamous Cell Carcinoma of Head and Neck
• Squamous Cell Carcinoma of the Head and Neck
• Squamous Cell Carcinoma of the Oral Cavity

Intervention

Drug:
• cRGD-ZW800-1.
Injection of cRGD-ZW800-1 within 48 hours before imaging/surgery

Locations

Country	Name	City	State
Netherlands	Erasmus University Medical Center	Rotterdam	Zuid-Holland

Sponsors (1)

Lead Sponsor	Collaborator
Erasmus Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	WP-I: (Highest) mean tumor-to-background ratio (TBR)	Two dosages of cRGD-ZW800-1 are tested in two groups of each 7 patients. An expansion cohort (n=14) will be added to the dose group that yields the highest TBR.	up to 48 ours post-dose
Primary	WP-II: Rate of adequate (i.e. >5mm clear) tumor resection margins.		through histopathology, up to max 4 weeks post-op
Secondary	WP-II: Sensitivity, specificity, positive and negative predictive values		through histopathology, up to max 4 weeks post-op
Secondary	WP-II: Co-localization of FLI with immunohistochemistry on pathology slides		through histopathology, up to max 4 weeks post-op
Secondary	WP-II: Percentage of extra tissue resection based on FLI-driven frozen sections		through histopathology, up to max 4 weeks post-op
Secondary	WP-II: Operation time		through histopathology, up to max 4 weeks post-op
Secondary	WP-II: FLI of lymph node metastases after neck dissection		through histopathology, up to max 4 weeks post-op

External Links

•   First in-human study of cRGD-ZW800-1 in patients with colorectal cancer